For more than a decade, Guardant Health has helped patients across
the continuum of care
in cancer4
For more than a decade, Guardant Health has helped patients across
the continuum of care
in cancer4
References: 1. Chung DC, Gray DM II, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024;390(11):973-983. doi:10.1056/NEJMoa2304714 2. Coronado GD, Jenkins CL, Shuster E, et al. Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence. Gut. 2024;73(4):622-628. doi:10.1136/gutjnl-2023-330980 3. Data on file. Guardant Health, Inc. 4. Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications. May 21, 2024. Accessed June 3, 2024. https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Receives-EU-IVDR-Certification-for-Guardant360-CDx-Liquid-Biopsy-for-Tumor-Mutation-Profiling-Across-All-Solid-Cancers-and-Companion-Diagnostic-Indications/default.aspx
